Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ODTX
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. (ODTX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
C+
Factor Score
2.5
/ 5.0
Growth
C
Factor Score
2.2
/ 5.0
Profitability
D-
Factor Score
0.8
/ 5.0
Momentum
C+
Factor Score
2.8
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-4.5
EV / EBITDA
-3.9
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-3.0%
Price Return 12M
22.4%
Catalyst Signal
0.00
Market Cap
$966.2M
TTM Revenue
$0.0
Price / Sales
N/A
ROE
N/A
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C (2.2) | D- (0.8) | C+ (2.8) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | D+ (1.7) | D- (0.8) | B- (2.9) | C+ (2.7) | C- (2.1) |
| 2026-10-30 | F (0.0) | D+ (1.6) | D- (0.8) | B+ (3.6) | C+ (2.7) | D+ (1.7) |
| 2026-10-23 | F (0.0) | C- (1.9) | D- (0.8) | B (3.2) | C+ (2.6) | D+ (1.7) |
| 2026-10-16 | F (0.0) | C- (1.9) | D- (0.8) | B+ (3.5) | C+ (2.6) | D+ (1.8) |
Page
1
of
4